Related Experiment Video
Updated: Jan 17, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Timosaponin A3 Ameliorates Prostate Cancer Progression via Upregulating STARD4 Mediated Cholesterol Metabolism
Ye Zhi1, Luqi Ge1, Shaoru Wang1
1Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Abstract:
Prostate cancer (PCa) is a common and aggressive malignancy in men, often diagnosed at advanced stages with a poor five-year survival rate. Despite therapeutic advances, effective treatments for castration-resistant PCa remain lacking. Timosaponin A3 (TA3), a natural steroidal saponin derived from Anemarrhena asphodeloides Bunge, has shown potential anti-tumor properties, but its role in PCa and the underlying mechanisms have not been fully elucidated. In this study, we demonstrate that TA3 significantly inhibits the proliferation, migration, and invasion of PCa cells in vitro, and suppresses tumor growth in xenograft models. Transcriptomic analysis revealed that TA3 exerts its anti-tumor effects by modulating cholesterol metabolism. Elevated cholesterol levels were observed in PCa patients, and exogenous cholesterol administration reduced tumor growth in vivo. Notably, TA3 treatment upregulated the lipid transporter StAR related lipid transfer domain containing 4 (STARD4), a key regulator of cholesterol transport, which was confirmed to mediate the inhibitory effects of TA3 on PCa progression. Overexpression of STARD4 attenuated PCa development both in vitro and in vivo, while STARD4 knockdown abolished these effects. Collectively, our findings suggest that TA3 suppresses PCa progression by enhancing cholesterol metabolism via STARD4 upregulation, supporting its potential as a novel therapeutic agent for prostate cancer.
Insights
Timosaponin A3 (TA3) inhibits prostate cancer (PCa) progression by enhancing cholesterol metabolism. This natural compound upregulates STARD4, a key lipid transporter, offering potential as a novel PCa therapeutic.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer (PCa) is a prevalent malignancy with limited treatment options for advanced stages.
- Castration-resistant PCa (CRPC) presents a significant therapeutic challenge.
- Timosaponin A3 (TA3), a steroidal saponin, shows anti-tumor potential, but its mechanism in PCa is unclear.
Purpose of the Study:
- To investigate the anti-cancer effects of Timosaponin A3 (TA3) on prostate cancer (PCa).
- To elucidate the underlying molecular mechanisms of TA3's action in PCa.
- To evaluate TA3 as a potential therapeutic agent for PCa.
Main Methods:
- In vitro assays assessing PCa cell proliferation, migration, and invasion.
- In vivo xenograft models to evaluate tumor growth suppression.
- Transcriptomic analysis to identify TA3-modulated pathways.
- Molecular experiments involving STARD4 (StAR related lipid transfer domain containing 4) manipulation.
Main Results:
- TA3 significantly inhibited PCa cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo.
- TA3 modulated cholesterol metabolism and upregulated the expression of STARD4.
- STARD4 mediated TA3's anti-cancer effects, as its overexpression attenuated PCa development and knockdown abolished TA3's effects.
Conclusions:
- TA3 suppresses PCa progression by enhancing cholesterol metabolism through STARD4 upregulation.
- STARD4 plays a crucial role in mediating the anti-tumor effects of TA3 in prostate cancer.
- TA3 demonstrates potential as a novel therapeutic strategy for prostate cancer.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...